Compare SPCE & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCE | SLGL |
|---|---|---|
| Founded | 2017 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.2M | 240.3M |
| IPO Year | 2017 | 2016 |
| Metric | SPCE | SLGL |
|---|---|---|
| Price | $2.62 | $73.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $3.06 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 34.3M | 22.0K |
| Earning Date | 05-14-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,544,000.00 | N/A |
| Revenue This Year | $2,270.73 | N/A |
| Revenue Next Year | $880.03 | $223.84 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.13 | $7.09 |
| 52 Week High | $8.90 | $97.97 |
| Indicator | SPCE | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 41.29 | 51.44 |
| Support Level | $2.34 | $70.05 |
| Resistance Level | $2.68 | $75.00 |
| Average True Range (ATR) | 0.27 | 4.83 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 9.27 | 40.71 |
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.